Table 1.
Interventional clinical trials targeting cancer stem cells since 2020
| Identifier | Condition or disease | Intervention/treatment | Number of participants |
|---|---|---|---|
| NCT02423811 | Esophageal squamous cell carcinoma | Fursultiamine (a dietary Supplement) in addition to Concurrent chemoradiotherapy | 20 |
| NCT03949283 | Recurrent Ovarian Carcinoma; Platinum-resistant Ovarian Cancer | Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy | 220 |
| NCT03632798 | Recurrent Ovarian Cancer | Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing | 300 |
| NCT03632135 | Recurrent Glioblastoma | Standard Chemotherapy Versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing | 300 |
| NCT02654964 | Glioblastoma Multiforme | Combination Drug Therapy Based on Personalized Cancer Stem Cell High-Throughput Drug Screening | 10 |
| NCT02089919 | Metastatic Adenocarcinoma of the Liver | Cancer Stem Cell Vaccine | 40 |
| NCT02074046 | Metastatic Adenocarcinoma of the Pancreas | Cancer Stem Cell Vaccine | 40 |
| NCT02115958 | Lung Neoplasms (Metastatic of the Nasopharynx) | Cancer Stem Cell Vaccine | 40 |
| NCT02084823 | Metastatic Adenocarcinoma of the Lung | Cancer Stem Cell Vaccine | 40 |
| NCT02178670 | Metastatic Adenocarcinoma of the Ovarian | Cancer Stem Cell Vaccine | 40 |
| NCT02176746 | Metastatic Adenocarcinoma of the Colorectal | Cancer Stem Cell Vaccine | 40 |
| NCT03548571 | Glioblastoma | Dendritic Cell Immunotherapy | 60 |
| NCT01190345 | Breast Cancer | Pre-operative Bevacizumab in Combination With Chemotherapy | 75 |
| NCT01579812 | Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | Metformin | 90 |
| NCT01440127 | Colon Cancer | Metformin | 9 |
| NCT02859415 | Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms, Germ Cell and Embryonal Neoplasms | Continuous 24 h Intravenous Infusion of Mithramycin | 60 |
| NCT01118975 | Breast Cancer Neoplasm Metastasis | Vorinostat and Lapatinib | 12 |
| NCT01624090 | Lung Cancer, Esophageal Cancer, Mesothelioma, Gastrointestinal Neoplasms, Breast Cancer | Mithramycin | 16 |
| NCT01195415 | Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer | Gemcitabine Hydrochloride and Vismodegib | 25 |
| NCT01255800 | Recurrent Head and Neck Cancer | Cetuximab and the Hedgehog Inhibitor IPI-926 | 9 |
| NCT01868503 | Locally Advanced or Locally Recurrent Breast Cancer | Concurrent Lapatinib and Radiotherapy | 7 |
| NCT01334047 | Recurrent Epithelial Ovarian Cancer | Autologous Dendritic Cells Loaded With Amplified Ovarian Cancer Stem Cell mRNA, hTERT and Survivin (Vaccine therapy) | 5 |
| NCT02370238 | Metastatic Breast Cancer | Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone | 156 |
| NCT01861054 | Breast Cancer | Reparixin | |
| 20 | |||
| NCT02001974 | Metastatic Breast Cancer | Paclitaxel + Reparixin | 33 |
| NCT00645333 | Metastatic Breast Cancer | MK-0752, Docetaxel, and Pegfilgrastim | 30 |
| NCT02775695 | Resectable Pancreatic Cancer | Doxycycline | 12 |
| NCT02010606 | Recurrent Glioblastoma | Vaccination With Autologous Dendritic Cells Pulsed With Lysate Derived From an Allogeneic Glioblastoma Stem-like Cell Line | 39 |